Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
April 18, 2019 Off

HitGen Announces Achievement of Milestone from DEL Discovery Alliance with Merck & Co., Inc., Kenilworth, NJ., USA

By BusinessWire

KENILWORTH, N.J. & CHENGDU, China–(BUSINESS WIRE)–HitGen Inc., announced today that it has achieved a milestone in its discovery alliance with…

April 18, 2019 Off

Seasonal Allergic Rhinitis – Pipeline Insight, 2019 – ResearchAndMarkets.com

By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Seasonal Allergic Rhinitis – Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering. The report offers…

April 18, 2019 Off

Postherpetic Neuralgia – Pipeline Insight, 2019 – ResearchAndMarkets.com

By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Postherpetic Neuralgia – Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering. The report offers comprehensive…

April 18, 2019 Off

Postherpetic Neuralgia – Pipeline Insight, 2019 – ResearchAndMarkets.com

By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Postherpetic Neuralgia – Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering. The report offers comprehensive…

April 18, 2019 Off

Viela Bio Receives U.S. FDA Breakthrough Therapy Designation for Inebilizumab for Treatment of Neuromyelitis Optica Spectrum Disorder

By BusinessWire

Designation based on positive primary analysis of pivotal study, N-MOmentum GAITHERSBURG, Md.–(BUSINESS WIRE)–Viela Bio today announced that the U.S. Food…

April 18, 2019 Off

Obsidian Therapeutics Announces Leadership Transition and Appoints Paul K. Wotton, Ph.D., as Chief Executive Officer

By BusinessWire

Experienced CEO brings expertise in product development, cell and gene therapies, and public biotechnology companies as Obsidian positions itself for…

April 18, 2019 Off

Obsidian Therapeutics Announces Leadership Transition and Appoints Paul K. Wotton, Ph.D., as Chief Executive Officer

By BusinessWire

Experienced CEO brings expertise in product development, cell and gene therapies, and public biotechnology companies as Obsidian positions itself for…

April 18, 2019 Off

Talaris Therapeutics, Inc. Announces $100M Series A Financing to Advance Its Novel, Allogeneic Cell Therapy Through Late-Stage Clinical Development

By BusinessWire

– Financing will support Phase 3 trial of FCR001 for living donor kidney transplant patients and additional Phase 2 studies…

April 18, 2019 Off

AqVida and Phyton Biotech Receive Approval from European Directorate of Quality Medicines for AqVida’s Cancer-fighting Paclitaxel Injectable Finished Dosage Formulation

By BusinessWire

FORT WORTH, Texas–(BUSINESS WIRE)–Phyton Biotech, a German/North American Plant Cell Fermentation (PCF®) technology company, and AqVida, a German oncology Finished…

April 18, 2019 Off

Talaris Therapeutics, Inc. Announces Promising Phase 2 Data of Novel, Allogeneic Cell Therapy in Living Donor Kidney Transplant Recipients

By BusinessWire

– FCR001 established durable immune tolerance in 70% of patients – Results support initiation of Phase 3 registration study later…

Posts pagination

Previous 1 … 3,263 3,264 3,265 … 3,606 Next

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine